LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Refractory or Relapsed Multiple Myeloma Clinical Trial

— LEGEND-2  

Official title:

A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03090659
• Other study ID #: LCAR-B38M
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 2, 2015
• Est. completion date: December 31, 2023

Study information

• Verified date: June 2023
• Source: Nanjing Legend Biotech Co.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of LCAR-B38M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple myeloma (r/r MM).

Description:

Multiple myeloma (MM) is a usually incurable malignancy of plasma cells. Current therapies for multiple myeloma often cause remissions, but nearly all patients eventually relapse and die, an clear unmet clinical needs. As early as mid-2014, the investigators have started to develop a series of proprietary CAR-T products to target B cell maturation antigen (BCMA), a cell surface molecule which the investigator believes to be a desirable target antigen for multiple myeloma. All pre-clinical data and CMC data for LCAR-B38M CAR-T cell technology has been established by mid-2015 and a phase I proof-of-concept clinical trial has been planned since then.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients must have a confirmed prior diagnosis of active multiple myeloma as defined by the updated IMWG criteria.

• Patients with refractory multiple myeloma. Clear BCMA expression must be detected on malignant plasma cells from either bone marrow or a plasmacytoma by flow cytometry or immunohistochemistry.

• Refractory disease:1) At least 3 prior regimens, which must at least have contained bortezomi. or 2) other circumstances identified by clinical doctors.

• Relapse criteria in NCCN clinical practice guidelines in Oncology: Multiple Myeloma (2016.V2)

Exclusion Criteria:

• Women of child-bearing potential or who are pregnant or breastfeeding.

• Have any active and uncontrolled infection: hepatitis B, hepatitis C, HIV, or other fatal viral and bacterial infection.

• Systemic corticosteroid steroid therapy of greater than 5 mg/day of prednisone or equivalent dose of another corticosteroid are not allowed within 2 weeks prior to either the required leukapheresis or the initiation of the conditioning chemotherapy regimen.

• Patients with any uncontrolled intercurrent illness or serious uncontrolled medical disorder.

• Patients with CNS metastases or symptomatic CNS involvement (including cranial neuropathies or mass lesions and spinal cord compression).

• History of allogeneic stem cell transplantation. Have active acute or chronic graft-versus-host-disease (GVHD), or require immunosuppressant medications for GVHD, within 6 months of enrollment.

• Patients with active autoimmune skin diseases such as psoriasis or other active autoimmune diseases such as rheumatoid arthritis.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Refractory or Relapsed Multiple Myeloma

Intervention

Biological:
• LCAR-B38M CAR-T cell injection

Locations

Country	Name	City	State
n/a

Sponsors (5)

Lead Sponsor	Collaborator
Nanjing Legend Biotech Co.	Jiangsu Provincial People's Hospital, Ruijin Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, Shanghai Changzheng Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	>= Grade 1 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment	Day 1-30 days after injection
Secondary	Anti-myeloma responses to LCAR-B38M cell treatment	by measuring the changes of aberrant immunoglobulin in serum	Day 1-36 months after three split doses
Secondary	Anti-myeloma responses to LCAR-B38M cell treatment	multiple myeloma cells in bone marrow.	Day 1-36 months after three split doses